

ABRAHAM J. HAMADEH
8TH DISTRICT, ARIZONA

WASHINGTON OFFICE
1722 LONGWORTH HOB
WASHINGTON, D.C. 20515
(202) 225-4576

DISTRICT OFFICE
12515 W. BELL ROAD, SUITE 104
SURPRISE, AZ 85378
(623) 776-7911



COMMITTEE ON ARMED SERVICES
COMMITTEE ON VETERANS' AFFAIRS

Congress of the United States
House of Representatives
Washington, DC 20515

August 15, 2025

The Honorable Martin Makary
Commissioner
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993

Dear Commissioner Makary:

I write to express serious concern regarding recent FDA actions that may impact the availability of desiccated thyroid medications, particularly medications which contains bovine and porcine thyroid extracts. My office has been contacted by constituents who rely on these medications and are deeply concerned about potential market restrictions.

Arizona's 8th Congressional District has a significant veteran and senior population who depend on consistent access to thyroid medications. Many of these patients have found desiccated thyroid medications to be more effective than synthetic alternatives for managing their thyroid conditions. Any disruption to their treatment regimens could have serious health consequences and undermine the doctor-patient relationship.

I respectfully request the FDA provide answers to the following questions by September 5, 2025:

1. What specific actions, if any, is the FDA taking regarding desiccated thyroid medications like Armour Thyroid?
2. What evidence supports any potential restrictions on these long-established medications that have been safely used for decades?
3. Has the FDA conducted a comprehensive analysis of how any restrictions would affect patients who rely on these medications?
4. If restrictions are being considered, what steps will the FDA take to ensure patients maintain access to effective thyroid treatment options?

This issue reflects broader concerns about federal agency overreach into medical decisions that should remain between patients and their physicians. The FDA's primary mission should be ensuring drug safety and efficacy, not unnecessarily restricting access to medications with established track records of safety and effectiveness.

Given the urgency of this matter for affected patients, I request a written response by September 5th, 2025 detailing the FDA's current position and any planned actions regarding desiccated thyroid medications.

The people of Arizona's 8th District deserve transparency and assurance that their access to essential medications will not be disrupted by unnecessary regulatory actions. Should you have any questions, please contact my Legislative Director Cam Erickson at Cameron.Erickson@mail.house.gov. I look forward to your prompt response and to working together to ensure patients maintain access to the thyroid treatments they need.

Sincerely,

A handwritten signature in black ink, appearing to read 'A. Hamadeh', with a long horizontal flourish extending to the right.